Summarized by Masters of Longevity from PR Newswire.
A news article previewing a strategic merger in radiopharmaceuticals that creates a vertically integrated company with expanded manufacturing and development reach.
Key Takeaways
- Telix will acquire ITM, creating a combined organization with a large isotope manufacturing and distribution network.
- ITM-11 (177Lu-edotreotide) has completed one Phase 3 trial and an expansion Phase 3 study is fully enrolled with interim analysis due in H1 2027.
- Management projects unaudited pro forma 2026 revenue and income exceeding US$1.3 billion and targets positive EBITDA contribution from 2027.
